1.
M. Shimamura, J. Kim, A. K. Medoro et al., “Agreement Between Dried Blood Spot and Plasma PCR in Infants With Congenital Cytomegalovirus Infection,” Journal of Medical Virology, 97 (2025): e70257. https://doi.org/10.1002/jmv.70257.
In Table 1, the legend has been modified to denote that numbers in brackets [] indicate interquartile range. The correct table is shown below.
Table 1.
Clinical characteristics of infants with cCMV infection.
| ALL | DBS/Plasma | p‐valuea | ||||
|---|---|---|---|---|---|---|
| N = 70 | +/+ N = 49 | +/− N = 1 | −/+ N = 14 | −/− N = 6 | ||
| Sex | ||||||
| Female | 30 (43%) | 21 | 0 | 5 | 4 | |
| Male | 40 (57%) | 28 | 1 | 9 | 2 | |
| Race | ||||||
| White | 51 (73%) | 36 | 1 | 9 | 5 | |
| Black | 13 (19%) | 9 | 0 | 3 | 1 | |
| Asian | 3 (4%) | 2 | 0 | 1 | 0 | |
| Bi/Multiracial | 3 (4%) | 2 | 0 | 1 | 0 | |
| Other | 0 | 0 | 0 | 0 | 0 | |
| Ethnicity | ||||||
| Hispanic | 3 (4%) | 1 | 0 | 2 | 0 | |
| Non‐Hispanic | 67 (96%) | 48 | 1 | 12 | 6 | |
| Gestational ageb | 38 [37–39] | 38 [37–39] | 40 | 37 [36–39] | 39 [37–39] | n.s |
| Birth weightb | 2531 [2095–2935] | 2705 [2185–2938] | 2684 | 2325 [1871–2933] | 2261 [1910–2878] | n.s. |
| Birth lengthb | 47.0 [44.5–49.5] | 48.3 [45.5–49.9] | 45.7 | 44.75 [43.0–49.5] | 45.85 [42.7–48.65] | n.s. |
| Birth head circumferenceb | 32.0 [31.0–33.5] | 32.0 [31.0–33.5] | 33.0 | 31.0 [29.8–33.8] | 31.0 [29.1–32.4] | n.s. |
| Symptoms | ||||||
| Asymptomatic | 16 (23%) | 10 (20%) | 0 | 5 (36%) | 1 (17%) | |
| Symptomatic | 54 (77%) | 39 (80%) | 1 (100%) | 9 (64%) | 5 (83%) | |
| Non‐CNS | 23 | 12 | 1 | 6 | 4 | |
| CNS | 31 | 27 | 0 | 3 | 1 | |
| SNHL | 18 | 16 | 0 | 1 | 1 | |
Abbreviations: CNS, central nervous system; DBS, dried blood spot; SNHL, sensorineural hearing loss.
Kruskal–Wallis test.
Brackets denote interquartile range.
In Table 4, Column 2 (“Reference #”) has been deleted and replaced by reference numbers added to the first column. The correct table is as follows.
Table 4.
Studies reporting blood or DBS CMV PCR results in unscreened or select populations.
| Study first author [Reference] | Population | Results |
|---|---|---|
| A. Newborns screened for cCMV infection: DBS PCR | ||
| Yamagishi [24] | 1176 neonates enrolled within 14 days of delivery | DBS+ for 2/1176 (0.17%) |
| Engman [25] | 6060 neonates enrolled at birth | DBS+ for 12/6060 (0.2%) |
| Boppana [12] | 11422 neonates screened with single‐primer CMV PCR; 9026 neonates screened with two‐primer CMV PCR | DBS single‐primer PCR+ for 17/11422 (0.15%)DBS two‐primer PCR+ for 11/9026 (0.12%) |
| Moteki [26] | 9675 neonates enrolled at birth | DBS+ for 47/9667 (0.48%) |
| Dollard [13] | 12554 neonates enrolled at birth | DBS+ for 48/12554 (0.38%) |
| Kaye [11] | 60115 neonates via universal newborn screening | DBS + 184/60115 (0.31%) |
| B. Children with cCMV infection: plasma or serum PCR | ||
| Nelson [14] | 20 cCMV infected infants age < 21 days | Serum PCR+ for 19/20 (95%) |
| Paradiž [27] | 4 cCMV infected infants | Plasma PCR+ for 4/4 (100%) |
| Marsico [28] | 114 cCMV infected infants | Whole blood PCR+ for 101/114 (89%) |
| Vives‐Oñós [15] | 95 cCMV infected infants | Plasma PCR+ for 82/95 (86%) |
| Nagel [16] | 18 infants with cCMV infection | Whole blood PCR+ for 15/18 (83%) |
| Fourgeaud [17] | 256 infants with cCMV infection at age 0–30 days | Whole blood PCR+ for 147/159 (92%) |
| C. Children with cCMV infection: DBS PCR | ||
| Walter [29] | 39 children with cCMV infection | DBS+ for 28/39 (72%) |
| Boppana [12] | 92 infants with cCMV infection | DBS single‐primer PCR+ for 17/60 (28%) DBS two‐primer PCR+ for 11/32 (34%) |
| Paradiž [27] | 4 cCMV infected infants | DBS+ for 2/4 (50%) |
| Vives‐Oñós [15] | 103 infants with cCMV infection | DBS+ for 58/103 (56%) |
| Dollard [13] | 56 newborns with cCMV infection | DBS+ for 48/56 (86%) |
| Almeida [30] | 1388 children enrolled: symptomatic cCMV (n = 779), maternal primary CMV infection (n = 75), or no information (n = 534) | DBS+ for 104/1388 (7.5%) DBS+ for 52/779 (6.7%) symptomatic cCMV |
| D. Children with hearing loss: DBS PCR | ||
| Barbi [31] | 125 children with hearing loss > 40 dB of unknown etiology | DBS+ for 9/87 (10%) with early onset hearing loss and 13/38 (34%) with late onset hearing loss |
| Walter [29] | 41 children with unexplained SNHL | DBS+ for 9/35 (26%) |
| Boudewyns [32] | 96 infants with SNHL | DBS+ for 7/96 (7%) |
| Choi [33] | 958 infants who did or did not pass NBHS | DBS+ for 13/479 (2.7%) who did not pass NBHS and 2/479 (0.4%) who passed NBHS |
| Korver [34] | 179 children with SNHL | DBS+ for 14/179 (8%) |
| Karltorp [35] | 91 children with SNHL | DBS+ for 18/91 (20%) |
| Courtmans [36] | 75 children with SNHL | DBS+ for 8/75 (10%) |
| Toumpas [37] | 106 children with moderate to profound SNHL | DBS+ for 9/106 (8.5%) |
| Meyer [38] | 57 children with unexplained SNHL | DBS+ for 15/57 (26%) |
| Lee [39] | 114 children with unexplained SNHL | DBS+ for 6/114 (5.3%) |
| Pellegrinelli [40] | 82 children with SNHL | DBS+ for 5/82 (6%) |
| Liao [41] | 333 children with SNHL | DBS+ for 15/333 (4.5%) |
Abbreviations: cCMV, congenital cytomegalovirus; DBS+, dried blood spot (PCR) positive; NBHS, newborn hearing screen; PCR, polymerase chain reaction; SNHL, sensorineural hearing loss.
We apologize for the error.